NUVL
Nuvalent, Inc.
Latest Form 4:Sale$261KbyPelish Henry E. (Chief Scientific Officer) · filed Jul 10, 2026
Nuvalent, Inc. (NUVL) has 83 SEC Form 4 filings (322 transaction rows) in the rolling window, disclosed by 8 distinct insiders. Most recent filing: Jul 15, 2026.
The most active filer is Chief Financial Officer Balcom Alexandra with 17 filings. Insiders have net sold $39.6M over the trailing 6 months.
- Industry:Biotechnology
- CEO:James R. Porter
- Employees:234
- HQ:Cambridge, MA, US
- IPO:2021-07-29
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$115.8M
reported sales (SEC code S)
Unique Insiders
8
in the rolling window
| Source | ||||||
|---|---|---|---|---|---|---|
| Chief Scientific Officer | Sale | 2,111 | $261K | Jul 10 | SEC ↗ | |
| President and CEO | Sale | 30,000 | $3.7M | Jul 8 | SEC ↗ | |
| Chief Financial Officer | Sale | 11,430 | $1.4M | Jul 6 | SEC ↗ | |
| Chief Development Officer | Sale | 23,000 | $2.8M | Jul 6 | SEC ↗ | |
| Chief Development Officer | Sale | 5,500 | $679K | Jul 1 | SEC ↗ | |
| Chief Development Officer | Sale | 20,000 | $2.5M | Jun 11 | SEC ↗ | |
| President and CEO | Sale | 30,000 | $2.7M | Jun 10 | SEC ↗ | |
| Chief Financial Officer | Sale | 11,430 | $1.1M | Jun 3 | SEC ↗ | |
| Chief Development Officer | Sale | 5,500 | $593K | Jun 1 | SEC ↗ | |
| Chief Legal Officer | Sale | 5,500 | $593K | Jun 1 | SEC ↗ | |
| President and CEO | Sale | 30,000 | $3.1M | May 6 | SEC ↗ | |
| Chief Financial Officer | Sale | 11,430 | $1.1M | May 5 | SEC ↗ | |
| Chief Legal Officer | Sale | 5,500 | $546K | May 1 | SEC ↗ | |
| Chief Development Officer | Sale | 5,500 | $548K | May 1 | SEC ↗ | |
| Chief Scientific Officer | Sale | 3,093 | $323K | Apr 13 | SEC ↗ | |
| President and CEO | Sale | 30,000 | $3.1M | Apr 8 | SEC ↗ | |
| Chief Financial Officer | Sale | 11,430 | $1.2M | Apr 3 | SEC ↗ | |
| Chief Development Officer | Sale | 5,500 | $538K | Apr 1 | SEC ↗ | |
| Chief Legal Officer | Sale | 5,500 | $543K | Mar 30 | SEC ↗ | |
| Chief Financial Officer | Sale | 11,430 | $1.1M | Mar 26 | SEC ↗ | |
| Chief Financial Officer | Sale | 13,700 | $1.4M | Mar 26 | SEC ↗ | |
| Chief Scientific Officer | Sale | 30,000 | $2.9M | Mar 16 | SEC ↗ | |
| Chief Scientific Officer | Sale | 5,104 | $505K | Mar 16 | SEC ↗ | |
| President and CEO | Sale | 30,000 | $3.0M | Mar 10 | SEC ↗ | |
| Chief Development Officer | Sale | 5,500 | $567K | Mar 2 | SEC ↗ | |
| Chief Legal Officer | Sale | 5,500 | $567K | Mar 2 | SEC ↗ | |
| Chief Development Officer | Sale | 5,500 | $561K | Feb 2 | SEC ↗ | |
| Chief Legal Officer | Sale | 700 | $77K | Jan 23 | SEC ↗ | |
| Chief Legal Officer | Sale | 14,300 | $1.6M | Jan 23 | SEC ↗ | |
| President and CEO | Sale | 17,890 | $1.7M | Jan 7 | SEC ↗ | |
| President and CEO | Sale | 9,543 | $927K | Jan 7 | SEC ↗ | |
| Chief Development Officer | Sale | 4,236 | $412K | Jan 7 | SEC ↗ | |
| Chief Development Officer | Sale | 3,181 | $309K | Jan 7 | SEC ↗ | |
| Chief Legal Officer | Sale | 4,363 | $425K | Jan 7 | SEC ↗ | |
| Chief Legal Officer | Sale | 2,589 | $252K | Jan 7 | SEC ↗ | |
Turner Christopher DurantFirst filing | Chief Medical Officer | Sale | 4,236 | $412K | Jan 7 | SEC ↗ |
Turner Christopher DurantFirst filing | Chief Medical Officer | Sale | 3,181 | $309K | Jan 7 | SEC ↗ |
| Chief Financial Officer | Sale | 4,236 | $412K | Jan 7 | SEC ↗ | |
| Chief Financial Officer | Sale | 3,181 | $309K | Jan 7 | SEC ↗ | |
| Chief Scientific Officer | Sale | 2,496 | $243K | Jan 7 | SEC ↗ | |
| Chief Scientific Officer | Sale | 2,664 | $259K | Jan 7 | SEC ↗ | |
| Chief Legal Officer | Sale | 10,000 | $1.0M | Jan 5 | SEC ↗ | |
| Chief Development Officer | Sale | 4,000 | $400K | Jan 2 | SEC ↗ | |
| Chief Financial Officer | Sale | 7,084 | $782K | Dec 10 | SEC ↗ | |
| Chief Development Officer | Sale | 4,000 | $434K | Dec 2 | SEC ↗ | |
| Director | Sale | 7,500 | $820K | Nov 26 | SEC ↗ | |
Flynn James EFirst filing | Director by Deputization | Sale | 371,287 | $35.4M | Nov 24 | SEC ↗ |
| Chief Financial Officer | Sale | 20,000 | $2.0M | Nov 19 | SEC ↗ | |
| Chief Financial Officer | Sale | 729 | $76K | Nov 19 | SEC ↗ | |
| Chief Legal Officer | Sale | 24,200 | $2.6M | Nov 19 | SEC ↗ | |
| Chief Legal Officer | Sale | 21,800 | $2.2M | Oct 31 | SEC ↗ | |
| Chief Development Officer | Sale | 4,000 | $412K | Oct 31 | SEC ↗ | |
Shair MatthewFirst filing | Director | Sale | 18,391 | $1.8M | Oct 29 | SEC ↗ |
Shair MatthewFirst filing | Director | Sale | 41,609 | $4.2M | Oct 29 | SEC ↗ |
| Chief Legal Officer | Sale | 5,000 | $475K | Oct 22 | SEC ↗ | |
| Chief Scientific Officer | Sale | 14,205 | $1.3M | Oct 17 | SEC ↗ | |
Miller Deborah AnnFirst filing | Chief Legal Officer | Sale | 15,624 | $1.4M | Oct 17 | SEC ↗ |
Miller Deborah AnnFirst filing | Chief Legal Officer | Sale | 12,376 | $1.1M | Oct 17 | SEC ↗ |
| President and CEO | Sale | 27,000 | $2.4M | Oct 17 | SEC ↗ | |
| Chief Financial Officer | Sale | 1,683 | $144K | Oct 17 | SEC ↗ | |
| Chief Scientific Officer | Sale | 7,637 | $686K | Oct 15 | SEC ↗ | |
| Chief Scientific Officer | Sale | 2,433 | $209K | Oct 15 | SEC ↗ | |
| Chief Financial Officer | Sale | 20,000 | $1.8M | Oct 15 | SEC ↗ | |
| Chief Financial Officer | Sale | 20,000 | $1.7M | Oct 15 | SEC ↗ | |
| Chief Financial Officer | Sale | 20,000 | $1.7M | Oct 3 | SEC ↗ | |
Balcom AlexandraFirst filing | Chief Financial Officer | Sale | 7,588 | $645K | Oct 1 | SEC ↗ |
Balcom AlexandraFirst filing | Chief Financial Officer | Sale | 20,000 | $1.7M | Oct 1 | SEC ↗ |
Noci DarleneFirst filing | Chief Development Officer | Sale | 4,000 | $332K | Oct 1 | SEC ↗ |
Porter James RichardFirst filing | President and CEO | Sale | 27,000 | $2.1M | Sep 17 | SEC ↗ |
Pelish Henry E.First filing | Chief Scientific Officer | Sale | 3,725 | $294K | Sep 12 | SEC ↗ |
Related companies
Nuvalent, Inc. is in the Healthcare sector.